Biopharmaceutical industry leader with more than two decades of broad management experience, supported by nearly a decade of prior experience as a practicing physician. Inspired to re-join the industry after an early retirement to help address the ongoing healthcare disparities facing the sickle cell disease community, and currently leading Global Blood Therapeutics, Inc. (GBT) on its mission to develop therapies for this underserved patient population. Currently serving on the board of directors of Royalty Pharma, Inc. and the Biotechnology Innovation Organization (BIO). Holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School; completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.